COCP RSI Chart
Last 7 days
15.0%
Last 30 days
39.2%
Last 90 days
26.8%
Trailing 12 Months
-13.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2020 | 1.9M | 1.9M | 1.9M | 2.0M |
2019 | 3.8M | 4.7M | 5.6M | 6.6M |
2018 | 0 | 0 | 2.0M | 2.9M |
2016 | 100.0K | 112.0K | 1.0M | 0 |
2015 | 6.2M | 4.1M | 2.1M | 78.0K |
2014 | 0 | 0 | 0 | 8.2M |
2013 | 15.9M | 12.9M | 10.3M | 0 |
2012 | 13.5M | 15.8M | 16.6M | 17.3M |
2011 | 14.6M | 14.0M | 13.4M | 12.8M |
2010 | 0 | 0 | 0 | 15.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 04, 2023 | frost phillip md et al | bought | 2,000,000 | 1.97 | 1,015,230 | - |
Aug 20, 2021 | pfenniger richard c jr | bought | 41,120 | 1.028 | 40,000 | - |
May 04, 2021 | schinazi raymond f | sold | -1,696,250 | 2.95 | -575,000 | - |
Oct 25, 2019 | schinazi raymond f | bought | 9,091 | 1.15 | 7,906 | - |
Oct 24, 2019 | schinazi raymond f | bought | 5,858 | 1.15 | 5,094 | - |
Oct 23, 2019 | schinazi raymond f | bought | 4,086 | 1.0386 | 3,935 | - |
Which funds bought or sold COCP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | VIMA LLC | added | 105 | 535 | 922 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -6,600 | 34,953 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -0.01 | -19,108 | 82,979 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -0.04 | -2,897 | 12,565 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 27.58 | 376 | 10,439 | -% |
May 15, 2024 | Royal Bank of Canada | added | 466 | - | - | -% |
May 14, 2024 | NORTHERN TRUST CORP | unchanged | - | -3,933 | 17,090 | -% |
May 13, 2024 | UBS Group AG | added | 12,030 | 28,073 | 28,361 | -% |
May 13, 2024 | FMR LLC | sold off | -100 | -7.00 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | -16,318 | 86,436 | -% |
Unveiling Cocrystal Pharma Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cocrystal Pharma Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Cocrystal Pharma Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2013Q3 | 2013Q2 | 2013Q1 |
Revenue | 4.3% | 510 | 489 | 554 | 461 | 402 | 492 | 592 | 5,078 | 3,818 | 2,559 | 1,299 | 39.00 | 49.00 | - | 24.00 | 27.00 | 714 | 1,400 | 2,087 | 1,956 | 2,029 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,110 | 552 | 592 |
Operating Expenses | -38.2% | 1,976 | 3,198 | 4,004 | 2,422 | 48,327 | 2,300 | 2,142 | 2,201 | 56,305 | 2,419 | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 14.0% | 1,278 | 1,121 | 2,028 | 1,139 | 1,266 | 1,223 | 1,051 | 1,323 | 1,196 | 952 | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | -66.4% | 698 | 2,077 | 1,976 | 1,283 | 958 | 1,077 | 1,091 | 878 | 1,204 | 1,467 | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 0% | 2.00 | 2.00 | 2.00 | 2.00 | 9.00 | 5.00 | 5.00 | -6.00 | -3.00 | 500* | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | -12,124 | -483 | - | - | - | 15,300 | - | -52.00 | - | - | - | - | - |
Earnings Before Taxes | - | - | - | - | - | -47,845 | -1,780 | -1,515 | 2,971 | -56,409 | -2,351 | -1,881 | -3,227 | - | - | - | - | - | - | -6,058 | - | - |
Net Income | 44.1% | -1,493 | -2,670 | -3,495 | -1,990 | -47,845 | -1,780 | -1,515 | 2,971 | -44,286 | -1,868 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -15.1% | 27.00 | 31.00 | 33.00 | 36.00 | 38.00 | 41.00 | 46.00 | 52.00 | 75.00 | 79.00 | 83.00 | 87.00 | 54.00 | 54.00 | 53.00 | 40.00 | 43.00 | 29.00 | 73.00 | 75.00 | 76.00 |
Current Assets | -15.8% | 24.00 | 29.00 | 32.00 | 36.00 | 37.00 | 40.00 | 45.00 | 52.00 | 55.00 | 59.00 | 62.00 | 67.00 | 34.00 | 34.00 | 33.00 | 20.00 | 23.00 | 8.00 | 7.00 | 9.00 | 10.00 |
Cash Equivalents | -17.1% | 22.00 | 26.00 | 30.00 | 32.00 | 34.00 | 37.00 | 42.00 | 51.00 | 55.00 | 59.00 | 62.00 | 67.00 | 33.00 | 33.00 | 32.00 | 19.00 | 22.00 | 7.00 | 6.00 | 7.00 | 9.00 |
Net PPE | -10.0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | - | - | - | - | - | - | - | - | - | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 65.00 | 65.00 | 65.00 |
Liabilities | -18.7% | 4.00 | 5.00 | 2.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.00 | 2.00 | 2.00 |
Current Liabilities | -27.1% | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 | 2.00 | 2.00 | 1.00 | 2.00 | 1.00 | 1.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Shareholder's Equity | -14.4% | 23.00 | 26.00 | 31.00 | 0.00 | 35.00 | 40.00 | 50.00 | 49.00 | 74.00 | 78.00 | 81.00 | 85.00 | 52.00 | 53.00 | 50.00 | 37.00 | 40.00 | 26.00 | 71.00 | 72.00 | 74.00 |
Retained Earnings | -1.3% | -319 | -315 | -311 | -307 | -303 | -297 | -293 | -287 | -263 | -259 | -255 | -251 | -247 | -244 | -243 | -240 | -237 | -235 | -187 | -185 | -184 |
Additional Paid-In Capital | 0.0% | 342 | 342 | 342 | 342 | 338 | 337 | 337 | 337 | 337 | 337 | 336 | 336 | 300 | 297 | 294 | 278 | 278 | 261 | 258 | 258 | 258 |
Shares Outstanding | 0.0% | 10.00 | 10.00 | 10.00 | 10.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 6.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 19.00 | - | - | - | 38.00 | - | - | - | 116 | - | - | - | 64.00 | - | - | - | 38,555 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -35.4% | -4,503 | -3,326 | -2,681 | -5,548 | -3,111 | -4,893 | -8,908 | -3,724 | -3,910 | -2,922 | -5,403 | -2,624 | -1,770 | -2,381 | -3,061 | -2,200 | -2,188 | -1,230 | -1,323 | -1,028 | 2,018 |
Share Based Compensation | -0.6% | 157 | 158 | 173 | 179 | 291 | 159 | 216 | 241 | 239 | 222 | 205 | 78.00 | 219 | 199 | 237 | 119 | 107 | 138 | 108 | 33.00 | 33.00 |
Cashflow From Investing | 86.4% | -8.00 | -59.00 | - | -14.00 | -45.00 | -12.00 | - | - | - | -8.00 | -4.00 | -15.00 | -25.00 | -1.00 | -19.00 | -127 | -93.00 | -1.00 | -115 | -4.00 | -25.00 |
Cashflow From Financing | - | - | - | - | 4,000 | -7.00 | -7.00 | -7.00 | -7.00 | -6.00 | -9.00 | -11.00 | 36,423 | 2,063 | 3,611 | 15,546 | -44.00 | 16,549 | 2,655 | -42.00 | -65.00 | 3,876 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 2,950 | $ 3,907 |
General and administrative | 1,208 | 1,204 |
Total operating expenses | 4,158 | 5,111 |
Loss from operations | (4,158) | (5,111) |
Other income (expense): | ||
Interest income (expense), net | 220 | |
Foreign exchange loss | (18) | (78) |
Total other income (expense), net | 202 | (78) |
Net loss | $ (3,956) | $ (5,189) |
Net loss per common share, basic | $ (0.39) | $ (0.64) |
Net loss per common share, diluted | $ (0.39) | $ (0.64) |
Weighted average number of common shares, basic | 10,174 | 8,143 |
Weighted average number of common shares, diluted | 10,174 | 8,143 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash | $ 21,842,000 | $ 26,353,000 |
Restricted cash | 75,000 | 75,000 |
Tax credit receivable | 1,003,000 | 890,000 |
Prepaid expenses and other current assets | 1,572,000 | 1,773,000 |
Total current assets | 24,492,000 | 29,091,000 |
Property and equipment, net | 244,000 | 271,000 |
Deposits | 46,000 | 46,000 |
Operating lease right-of-use assets, net (including $26 and $42 to related party) | 1,764,000 | 1,851,000 |
Total assets | 26,546,000 | 31,259,000 |
Current liabilities: | ||
Accounts payable and accrued expenses | 2,139,000 | 3,022,000 |
Current maturities of operating lease liabilities (including $26 and $42 to related party) | 240,000 | 240,000 |
Total current liabilities | 2,379,000 | 3,262,000 |
Long-term liabilities: | ||
Operating lease liabilities (including $0 and $0 to related party) | 1,582,000 | 1,613,000 |
Total long-term liabilities | 1,582,000 | 1,613,000 |
Total liabilities | 3,961,000 | 4,875,000 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Common stock, $0.001 a par value: 150,000 shares authorized as of March 31, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 10,000 | 10,000 |
Additional paid-in capital | 342,445,000 | 342,288,000 |
Accumulated deficit | (319,870,000) | (315,914,000) |
Total stockholders’ equity | 22,585,000 | 26,384,000 |
Total liabilities and stockholders’ equity | $ 26,546,000 | $ 31,259,000 |